Aleniglipron Hepatic Impairment Study

Part of paid clinical trials in Orlando, Florida.

Sponsor
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Study ID
NCT07872033
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Hepatic Impairment

Eligibility Criteria

Sex
ALL
Age
18 Years - 85 Years
Healthy Volunteers
Not accepted

Interventions

  • Aleniglipron — DRUG
    administered orally

Study Details

The purpose of this study is to evaluate the PK of aleniglipron in participants with Hepatic Impairment to establish scientifically guided dosing recommendations in these special patient populations.

Key Dates

First listed
Oct 13, 2026
Start date
Oct 31, 2026
Status verified
Oct 2026
Primary completion
Aug 31, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
36 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
OTHER

Arms

  • Experimental: Participants will receive aleniglipron administered orally Part 1
  • Experimental: Participants will receive aleniglipron administered orally Part 2

Primary Outcome Measure

PK parameters including but not limited to AUC0-t [ Time Frame: Baseline to Day 5 (Part 1) ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Research SiteOrlandoFlorida32809
Medical Director
[email protected]
650-457-1959
Research SiteSan AntonioTexas78215
Medical Director
[email protected]
650-457-1959

Related Studies